NCT Number: NCT00222482
Depakote ER in Borderline Personality Disorder
This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.
Looking for future studies?
Notify MeKey information
Age range
21 year–55 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health -
Exclusion criteria
Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol.
-
Treatment and study plan
Primary outcomes
-
Symptom Checklist 90
Secondary outcomes
-
Barratt Impulsivity Scale
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
University of Minnesota
Other
Collaborators
- Abbott
- Schulz, S. Charles, M.D.
Registry information
Official study title
A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder
Important dates
- Study start
- 2003
- Study completion
- 2005
- First posted
- Sep 22, 2005
- Registry last updated
- Aug 9, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
NCT07001475
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Berlin, Germany
View Trial DetailsReal-time Experiences With Sleep Training Study
NCT04507308
Borderline Personality Disorder, Mental Disorders
London, Ontario, Canada
View Trial DetailsCircuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
NCT04130958
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial DetailsPersonality Change Study for Borderline Personality Disorder
NCT06005129
Borderline Personality Disorder, Mental Disorders
Lexington, Kentucky, United States
View Trial Details